APA (7th ed.) Citation

DV, C., YK, K., HE, U., KW, L., MC, N., PC, E., . . . H, P. (2023). Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. Oncology (Williston Park, N.Y.), 37(4), 176. https://doi.org/10.46883/2023.25920992

Chicago Style (17th ed.) Citation

DV, Catenacci, et al. "Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma." Oncology (Williston Park, N.Y.) 37, no. 4 (2023): 176. https://doi.org/10.46883/2023.25920992.

MLA (9th ed.) Citation

DV, Catenacci, et al. "Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma." Oncology (Williston Park, N.Y.), vol. 37, no. 4, 2023, p. 176, https://doi.org/10.46883/2023.25920992.